Correlates of left ventricular mass in chronic hemodialysis recipients

  • Ron Wald
  • Marc B. Goldstein
  • Rachel M. Wald
  • Ziv Harel
  • Anish Kirpalani
  • Jeffrey Perl
  • Darren A. Yuen
  • Myles S. Wolf
  • Andrew T. Yan
Original Paper
First Online:
Received:
Accepted:

Abstract

We aimed to clarify the correlates of left ventricular mass and secondarily, left ventricular volume, in a cohort of prevalent hemodialysis recipients. Left ventricular hypertrophy is common and left ventricular mass is a widely-accepted surrogate for clinical outcomes in dialysis recipients, who are often subjected to chronic pressure and volume overload. However, the precise pathophysiologic mechanisms of left ventricular hypertrophy in this unique population have not been well understood. This was a cross-sectional study of patients receiving conventional thrice-weekly dialysis in Toronto, Canada. Left ventricular mass and volume were assessed with cardiac magnetic resonance and indexed to the patient’s height to the power of 2.7. Fibroblast growth factor-23 concentration was measured using a C-terminal enzyme-linked immunosorbent assay. Patient demographics, comorbidities, dialysis-associated blood pressures and ultrafiltration volumes, biochemical and hematologic parameters, vascular access and medications were extracted from clinical records. Multivariable linear regression was used to identify independent correlates of left ventricular mass index (LVMI) and the left ventricular end diastolic volume index (LVEDVI). We enrolled 56 patients, of whom 23 (41.1 %) were women with mean age 54 ± 12 years. Mean LVMI was 31.1 ± 6.8 g/m2.7. In multivariable analyses, systolic blood pressure and LVEDVI were the only factors significantly associated with LVMI. Post-dialysis weight, percent reduction in urea and the presence of a permanent form of vascular access were associated with LVEDVI. Fibroblast growth factor-23 was not associated with either LVMI or LVEDVI. Blood pressure and left ventricular dilatation are independent determinants of elevated left ventricular mass. Aggressive blood pressure reduction and avoidance of volume overload may confer LVM regression and improve clinical outcomes.

Keywords

Hemodialysis Left ventricular hypertrophy Left ventricular volume Cardiac magnetic resonance 

Abbreviations

CMR

Cardiac magnetic resonance

GFR

Glomerular filtration rate

IQR

Interquartile range

LVMI

Left ventricular mass index

LVEDVI

Left ventricular end diastolic volume index

FGF-23

Fibroblast growth factor-23

This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The investigators appreciate the efforts of the study our coordinators Stella Curvelo, Niki Dacouris, Galo Ginnochio Rosa Marticorena and Patricia Wahl. We are also grateful to Dr. Asad Merchant for tabulating the blood pressure data. The study was funded by an operating grant from the Canadian Institutes of Health Research (R.Wald, M.B. Goldstein, A. Yan).

Conflict of interest

M.S.W. has served as a consultant or received honoraria from Abbott, Amgen, Diasorin, Genzyme, Kai, Luitpold, Pfizer, Shire and Vifor Pharma.

References

  1. 1.
    Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC et al (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186–192PubMedCrossRefGoogle Scholar
  2. 2.
    London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B et al (2001) Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12:2759–2767PubMedGoogle Scholar
  3. 3.
    Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE (2000) Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11:912–916PubMedGoogle Scholar
  4. 4.
    Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B et al (2004) Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65:1492–1498PubMedCrossRefGoogle Scholar
  5. 5.
    Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR et al (2007) Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 298:1291–1299PubMedCrossRefGoogle Scholar
  6. 6.
    Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ et al (2010) In-center hemodialysis six times per week versus three times per week. N Engl J Med 363:2287–2300PubMedCrossRefGoogle Scholar
  7. 7.
    Rocco MV, Lockridge RS Jr, Beck GJ, Eggers PW, Gassman JJ, Greene T et al (2011) The effects of frequent nocturnal home hemodialysis: the frequent hemodialysis network nocturnal trial. Kidney Int 80:1080–1091PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS (1995) Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47:884–890PubMedCrossRefGoogle Scholar
  9. 9.
    White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ (1987) Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76:44–51PubMedCrossRefGoogle Scholar
  10. 10.
    De Winter O, De Sutter J, Dierckx RA (2002) Clinical relevance of left ventricular volume assessment by gated myocardial SPET in patients with coronary artery disease. Eur J Nucl Med Mol Imaging 29:957–966PubMedCrossRefGoogle Scholar
  11. 11.
    Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J et al (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A et al (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Jakubovic BD, Wald R, Goldstein MB, Leong-Poi H, Yuen DA, Perl J et al (2013) Comparative assessment of 2-dimensional echocardiography vs cardiac magnetic resonance imaging in measuring left ventricular mass in patients with and without end-stage renal disease. Can J Cardiol 29(3):384–390Google Scholar
  15. 15.
    Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S (2005) Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 7:775–782PubMedCrossRefGoogle Scholar
  16. 16.
    Palmieri V, de Simone G, Arnett DK, Bella JN, Kitzman DW, Oberman A et al (2001) Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). Am J Cardiol 88:1163–1168PubMedCrossRefGoogle Scholar
  17. 17.
    Cuspidi C, Meani S, Negri F, Giudici V, Valerio C, Sala C et al (2009) Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives? J Hum Hypertens 23:728–734PubMedCrossRefGoogle Scholar
  18. 18.
    Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307:674–684PubMedCrossRefGoogle Scholar
  19. 19.
    Lin FY, Devereux RB, Roman MJ, Meng J, Jow VM, Jacobs A et al (2008) Cardiac chamber volumes, function, and mass as determined by 64-multidetector row computed tomography: mean values among healthy adults free of hypertension and obesity. JACC Cardiovasc Imaging 1:782–786PubMedCrossRefGoogle Scholar
  20. 20.
    Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M et al (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 152:640–648PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al (1998) Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48–54PubMedCrossRefGoogle Scholar
  22. 22.
    Konstam MA, Udelson JE, Anand IS, Cohn JN (2003) Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail 9:350–353PubMedCrossRefGoogle Scholar
  23. 23.
    Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al (2004) Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110:1456–1462PubMedCrossRefGoogle Scholar
  24. 24.
    Foley RN, Curtis BM, Randell EW, Parfrey PS (2010) Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 5:805–813PubMedCrossRefGoogle Scholar
  25. 25.
    Patel RK, Oliver S, Mark PB, Powell JR, McQuarrie EP, Traynor JP et al (2009) Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging. Clin J Am Soc Nephrol 4:1477–1483PubMedCrossRefGoogle Scholar
  26. 26.
    Albugami MM, Panek R, Soroka S, Tennankore K, Kiberd BA (2012) Access to kidney transplantation: outcomes of the non-referred. Transplant Res 1(1):22Google Scholar
  27. 27.
    Chue CD, Edwards NC, Moody WE, Steeds RP, Townend JN, Ferro CJ (2012) Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 98:219–224PubMedCrossRefGoogle Scholar
  28. 28.
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218PubMedCrossRefGoogle Scholar
  29. 29.
    Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ et al (2011) Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305:1119–1127PubMedCrossRefGoogle Scholar
  30. 30.
    Wasse H, Singapuri MS (2012) High-output heart failure: how to define it, when to treat it, and how to treat it. Semin Nephrol 32:551–557PubMedCrossRefGoogle Scholar
  31. 31.
    Chan CT, Greene T, Chertow GM, Kliger AS, Stokes JB, Beck GJ et al (2012) Determinants of left ventricular mass in patients on hemodialysis: frequent hemodialysis network (FHN) trials. Circ Cardiovasc Imaging 5:251–261PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Stewart GA, Foster J, Cowan M, Rooney E, McDonagh T, Dargie HJ et al (1999) Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 56:2248–2253PubMedCrossRefGoogle Scholar
  33. 33.
    Constantine G, Shan K, Flamm SD, Sivananthan MU (2004) Role of MRI in clinical cardiology. Lancet 363:2162–2171PubMedCrossRefGoogle Scholar
  34. 34.
    Pennell DJ (2010) Cardiovascular magnetic resonance. Circulation 121:692–705PubMedCrossRefGoogle Scholar
  35. 35.
    Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115:41–46PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Ron Wald
    • 1
    • 2
  • Marc B. Goldstein
    • 1
    • 2
  • Rachel M. Wald
    • 2
    • 3
    • 4
  • Ziv Harel
    • 1
    • 2
  • Anish Kirpalani
    • 5
  • Jeffrey Perl
    • 1
    • 2
  • Darren A. Yuen
    • 1
    • 2
  • Myles S. Wolf
    • 6
  • Andrew T. Yan
    • 2
    • 7
  1. 1.Division of Nephrology, St. Michael’s HospitalUniversity of TorontoTorontoCanada
  2. 2.Li Ka Shing Knowledge InstituteSt. Michael’s HospitalTorontoCanada
  3. 3.Divisions of Cardiology and Medical ImagingUniversity Health NetworkTorontoCanada
  4. 4.Divisions of Cardiology and Medical ImagingUniversity of TorontoTorontoCanada
  5. 5.Department of Medical Imaging, St. Michael’s HospitalUniversity of TorontoTorontoCanada
  6. 6.Division of NephrologyNorthwestern University Feinberg School of MedicineChicagoUSA
  7. 7.Division of Cardiology, St. Michael’s HospitalUniversity of TorontoTorontoCanada

Personalised recommendations